March 20, 2013

Cambridge, MA, March 20, 2013 – ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6 through Wednesday, April 10, 2013, in Washington.

Listed below are the details of presentations at AACR that describe ARIAD’s product candidates. There will be four presentations of data on ARIAD’s targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:

Title: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC

Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)

Abstract: #2084

Location: Hall A-C, Poster Section 38


Title: Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers

Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)

Abstract: #2083

Location: Hall A-C, Poster Section 38


Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST

Date & Time: Tuesday, April 9, 8:00 a.m.–12:00 p.m. (Poster)

Abstract: #3394

Location: Hall A-C, Poster Section 42


Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML

Date & Time: Tuesday, April 9, 9:30–10:00 a.m. (Major symposium)

Presentation: #SY19-04

Location: Salon A-B, East Hall


Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions

Date & Time: Wednesday, April 10, 8:00 a.m.–12:00 p.m. (Poster)

Abstract: #5655

Location: Hall A-C, Poster Section 42 



ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.  ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.  ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.  For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).  


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.